Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel

Prospective Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel Infusion

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01448759

Acronym

ALCOOTAX

Enrollment

Registered

2011-10-07

Start date

2011-10-31

Completion date

2012-02-29

Last updated

2015-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumors

Keywords

Patients receiving docetaxel or paclitaxel. All tumors.

Brief summary

The purpose of this study is to evaluate plasma alcohol concentration in patients receiving Paclitaxel or Docetaxel infusion.

Detailed description

In this study, there is no experimental treatment, or experimental care.

Interventions

OTHERblood sampling

Other: Blood sampling 10mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.

Study design

Allocation

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Chemotherapy with docetaxel or paclitaxel on an every 3-week schedule. * Patient with bitherapy are eligible only if the taxane is the first infusion. * All type of tumor. * Age\>18 years old. * Signed written informed consent.

Exclusion criteria

* Patient under 18. * Patient with bitherapy, if docetaxel or paclitaxel is not administered first. * Patient deprived of liberty.

Design outcomes

Primary

Measure	Time frame	Description
Evaluation of plasma alcohol	One year	Measure of the plasma alcohol level before and after a taxane-based therapy (docetaxel or paclitaxel)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026